Effects of an Empowerment-based Psycho-behavioral Program on Persons With Mild Cognitive Impairment

NCT ID: NCT04723667

Last Updated: 2023-05-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

171 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2022-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the effects of a 13-week empowerment-based psycho-behavioral program to improve neuropsychiatric symptoms, cognitive functions, and health-related quality of life among persons with mild cognitive impairment. Its feasibility will be first evaluated in a pilot study and subsequently in a randomized controlled trial (RCT)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dementia has become a global pandemic. It affects 50 million people worldwide and this number is projected to have a three-fold increase to over 150 million by 2050. Dementia is characterized by a progressive deterioration in cognitive functions that interferes an individual to live independently. It jeopardizes the quality of life of the sufferers and their families and poses tremendous economic burden on health and social systems. In 2018, the total cost incurred by dementia worldwide was up to US$ 1 billion and it was forecasted to double in 2050. Since dementia is incurable, efforts to mitigate the burgeoning population of dementia should be directed to its prodromal reversible stage, that is, mild cognitive impairment (MCI).

MCI refers to the transitional stage between normal age-related cognitive decline and dementia. It is characterized by cognitive decline in a single or multiple cognitive domains including memory, executive functions, attention, language and visuospatial skills, but the ability to engage in activities of daily living is preserved. The global prevalence of MCI is 10 to 20% in persons aged 65 or older, and up to 25.9% for those aged above 80 years.

Current research effort focuses on addressing the cognitive symptoms of persons with MCI (PwMCI), least attention was paid to the co-existing neuropsychiatric symptoms (NPS). Such non-cognitive symptoms, indeed, affect persons in different stages of cognitive impairment, there is no exception for MCI. NPS is an umbrella term that captures psychological and behavioural symptoms, typical psychological symptoms encompass depression, apathy, and anxiety, which may cluster into a syndrome and precipitate behavioural symptoms such as agitation and disinhibition. Two systematic reviews simultaneously reported that up to 85% of the MCI population are afflicted with at least one of these symptoms, with depression being the most prevalent followed by anxiety and irritability. Comparing to those without such symptoms, they tend to have poorer quality of life, more severe functional loss, and with a fourfold increased risk for progression to dementia.

Despite the fact NPS is highly prevalence among PwMCI, effective management with comprehensive outcome measurement is yet to be determined. An empowerment-based, comprehensive multimodal intervention with MCI-specific outcome measurement on overall NPS is warranted. Such intervention should cover skills compensation with transferral into daily life, lifestyle reform, strength-based activity, cognitive restructuring, and disease-specific education. This study aims to evaluate an empowerment-based psycho-behavioral program on improving NPS, cognitive function and health-related quality of life among persons with MCI. This is a mix-methods study comprising an assessor-blinded randomized controlled trial and a descriptive qualitative study

As for the sample size calculation, the sample size of the pilot study was set based on a general rule of thumb of 30 participants, which has been shown adequate for exploring feasibility and outcome estimates to inform future trials. Those for the major study, Power analysis using G\*Power was performed to estimate the sample size for the RCT. According to the result of a systematic review that the pooled effect size of the non-pharmacological interventions on depression among persons with MCI was 0.47 (Lin et al., 2020), this study conservatively assumed the effect size of a similar but more comprehensive intervention on the primary outcome of NPS as 0.4. A sample size of 125 per study group is needed to achieve 80% power at a 5% level of significance, allowing a 20% attrition for a 17-week study.

Block randomization was used to allocate the participants to an intervention group, which received an empowerment-based psycho-behavioral program, or a control group, which received a health education program, at 1:1 ratio. The random sequence was generated by a computer randomization software on randomization.com. Each number was printed on a standard 2cm x 2cm memo and placed into an opaque and sealed envelope. To assure adequate allocation concealment, the allocation procedure was conducted by an independent research assistant who was not involved in this study.

For the quantitative data, all test comparisons were set at two-side at a level of significance of 0.05. The quantitative data were analyzed by SPSS Statistics (version 27) according to the intention-to-treat principle. Descriptive statistics were used to summarize the socio-demographic data, clinical profile, and outcome variables. The similarity of study groups at baseline was examined using chi-square test for categorical data and independent t-test for continuous data. All participants were assessed at baseline (T0), immediate post-test (T1), and four-week post-test (T2) to determine changes in their MBI-C, GDS-SF, AES, K10, HK-MoCA, MIC, and SF-12v2 scores. A generalized estimating equation (GEE) model was used to determine between- and within-group differences in outcome variables across three data collection timepoints. All statistical analyses were two-tailed with a 5% level of statistical significance. Effect size estimates were calculated for all mean differences using Cohen's d values, and were classified as negligible (d\<0.2), small (0.2≤ d\<0.5), medium (0.5≤d\< 0.8), or large (d≥0.8) effects (Lakens, 2013). Post-hoc power analysis was performed for all outcome variables using G\*Power software. Individual semi-structured interviews were conducted to explore the perceived effects of the psycho-behavioral program and the qualitative data were analyzed by content analysis.

Lin, R. S. Y., Yu, D. S. F., Chau, P. H., \& Li, P. W. C. (2021). An empowerment-psycho-behavioral program on neuropsychiatric symptoms in persons with mild cognitive impairment: Study protocol of a randomized controlled trial. Journal of Advanced Nursing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study aims to evaluate the effects of a 13-week empowerment-based psycho-behavioral program to improve neuropsychiatric symptoms, cognitive functions, and health-related quality of life among persons with mild cognitive impairment. A feasibility pilot study will be first evaluated in a pilot study among 30 participants with MCI and subsequently a full-scale randomized controlled trial will be conducted.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
The outcomes assessors were blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

13-week multimodal intervention

Group Type EXPERIMENTAL

13-week multimodal intervention

Intervention Type BEHAVIORAL

The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.

Active control

5-week health education programme

Group Type ACTIVE_COMPARATOR

5-week health education programme

Intervention Type BEHAVIORAL

The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

13-week multimodal intervention

The experimental intervention was a 13-week multimodal intervention consists of five-weekly, 90-minute, face-to-face sessions to be delivered in a group format (six to eight participants per group), followed by two weekly and three biweekly telephone follow-ups. The five face-to-face sessions covered brain health information, booster memory power, reducing stressors, optimizing strength and active lifestyle engagement.

Intervention Type BEHAVIORAL

5-week health education programme

The health education program consisted of three topics (fall prevention, oral care and home hygiene), with two tele-booster follow up

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 50 years old or above
2. Able to communicate in Cantonese
3. Diagnosis with MCI as defined by the following criteria:

I. Presence of significant cognitive complaints as reflected by self-report II. Abnormal objective cognitive performance defined as \< 1.5 standard deviations from age and education matched normal persons on Hong Kong Chinese version of Montreal Cognitive Assessment (HK-MoCA), which is a 12-item instrument measuring cognitive functions, more details are outlined under the session of outcome measures III. Independence in daily living as evaluated through clinical interviews

Exclusion Criteria

1. With the confirmed diagnosis of any forms of dementia
2. With the confirmed diagnosis of psychiatric morbidities, or history with stroke, brain injury and other neurological conditions that may affect cognitive, behavioral, and emotional functioning which may confound outcome measurement and limit their participation in the study
3. With hearing or visual impairment that may hinder participation in research activities
4. Current use of any cognitive intervention or electromagnetic stimulation that confound cognitive outcomes
Minimum Eligible Age

50 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rose Sin Yi Lin

PhD student

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rose Lin

Role: PRINCIPAL_INVESTIGATOR

The University of Hong Kong

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rose Lin

Hong Kong, , Hong Kong

Site Status

University of Hong Kong

Hong Kong, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

References

Explore related publications, articles, or registry entries linked to this study.

Lin RSY, Yu DSF, Pui Hing Chau P, Li PWC. An empowerment-psycho-behavioral program on neuropsychiatric symptoms in persons with mild cognitive impairment: Study protocol of a randomized controlled trial. J Adv Nurs. 2021 Aug;77(8):3507-3517. doi: 10.1111/jan.14871. Epub 2021 Apr 28.

Reference Type DERIVED
PMID: 33909293 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0000

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.